Sign in
Taking peoplePhase 1

Tests AZD0120 cell therapy in adults with relapsing or progressive multiple sclerosis

Tests whether a modified-immune-cell treatment is safe in adults with multiple sclerosis.

Key facts

Who runs it
AstraZeneca
Where
Cambridge and London, United KingdomSee the 2 sitesAlso in 4 other countries, 15 sites
Trial code
Registry title
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Status
Recruiting
Phase
Phase 1
People taking part
24 people, planned
Started
9 Dec 2025
Expected to end
12 Dec 2028
Type of study
Interventional, 2 groups
Treatments tested
  • AZD0120 - Regimen 1
  • AZD0120 - Regimen 2
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 60 with relapsing or progressive multiple sclerosis (MS) whose disease was not controlled by earlier strong MS medicines, or who could not tolerate them.

Age
18 to 60 years old at the time of consent.
Sex
All sexes can join.
Disease stage
Two groups. Relapsing MS (RMS), or relapsing active secondary progressive MS (SPMS), with EDSS (a disability score) of 6.5 or lower. Or primary progressive MS (PPMS), or non-relapsing SPMS, with EDSS from 3.0 to 6.5. RMS also needs signs of active disease within 2 years before screening.
Earlier treatment
Must have been on a high efficacy disease-modifying MS therapy for at least 6 months. In the RMS group, disease was still active on it, or the person could not tolerate it. In the progressive group, the response was inadequate to at least 1 such therapy, or the person could not tolerate it. Anyone who had CAR-T or CAR-NK cell treatment before cannot join.

Main reasons for not taking part

  • Prior CAR-T or CAR-NK cell treatment
  • Prior stem cell transplant or total lymphoid irradiation
  • HIV or HTLV infection, or active hepatitis
  • History of cancer, or other brain or nervous system disease such as epilepsy
  • Pregnant, breastfeeding, or planning pregnancy

The registry criteria, word for word

Show all 30 criteriaShow less

Who cannot take part

  • Any prior CAR-T or CAR-NK cell exposure
  • Underwent splenectomy within 12 months prior to signing the ICF
  • Received a solid organ transplant at any time or on an active transplant waiting list
  • Prior treatment with autologous hematopoietic stem cell transplantation or total lymphoid irradiation
  • Evidence of clinically significant bleeding or active bleeding diathesis within 90 days before screening
  • Major surgery within 4 weeks prior to apheresis or lymphodepletion or has surgery planned during the study or within 4 weeks after study treatment administration
  • Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 1 year after receiving study treatment, whichever is longer
  • Cardiac conditions or any other significant cardiac condition that would present undue risk to the participant in the investigator's opinion:
  • Any other central nervous system disease including epilepsy, convulsive seizures, organic encephalopathy syndrome, non-MS related paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease or associated movement disorder, psychosis, CNS vasculitis, or any other neurological disease that may impact the ability to evaluate neurotoxicity. History of a seizure disorder even if the seizure disorder is well controlled with anti-epileptics
  • Participant has significant psychiatric condition (active or history of)
  • History of other immune-mediated disease that required continued systemic immunosuppression/systemic disease-modifying agents
  • History of malignancy or ongoing treatment for prior malignancy
  • Seropositive for HIV or HTLV (including any history of HIV or HTLV)
  • Active viral (any etiology, HBV, HCV) hepatitis are excluded
  • Participants are excluded from the study if any of the following criteria apply:
  • Inborn error of immunity and/or primary immunodeficiency
  • Unwilling or unsafe to proceed with CSF exams based on coagulopathy or anatomy or other considerations in the judgment of the study investigator
  • Any contraindications to LP
  • Participants not willing, able, or are unsafe to take MRI scans as per protocol

Other criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Age
  • Age ≥ 18-years-old to ≤ 60-years-old at the time of consent; Type of Participant and Disease Characteristics
  • Written informed consent in accordance with federal, local, and institutional guidelines
  • Adequate physiological function and reserve at screening; RMS Cohort Specific Inclusion Criteria
  • Diagnosis of RMS according to the 2024 McDonald Criteria (Montalban et al 2025) or diagnosis of relapsing, active SPMS according to Lublin et al 2014
  • Participants should have an EDSS of ≤ 6.5 at screening
  • Evidence of active disease (clinical relapses and MRI activities within 2 years prior to screening), or intolerance, while on a high efficacy disease-modifying therapy for ≥ 6 months; PMS Cohort Specific Inclusion Criteria
  • Diagnosis of PPMS according to the 2024 McDonald Criteria (Montalban et al 2025) or non-relapsing SPMS according to Lublin et al 2014
  • Participants must have an EDSS of ≥ 3.0 and ≤ 6.5 at screening
  • Inadequate response ≥ 1 heDMT with ≥ 6 months treatment or intolerance

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Where in United Kingdom

Also in 4 other countries, 15 sites

  • CambridgeHospital not named in the registryNo longer taking part
  • LondonHospital not named in the registryNo longer taking part

About the trial

What the trial wants to find out

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.

The 2 groups in the trial

  • Arm/Group 1: AZD0120 RMSTreatment being tested

    AZD0120 RMS

    Treatment: AZD0120 - Regimen 1 and AZD0120 - Regimen 2

  • Arm/Group 2: AZD0120 PMSTreatment being tested

    AZD0120 PMS

    Treatment: AZD0120 - Regimen 1 and AZD0120 - Regimen 2

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults With Refractory Relapsing or Progressive Multiple Sclerosis
Plain-language title
Tests AZD0120 cell therapy in adults with relapsing or progressive multiple sclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07224373, who can take part
Record updated
25 August 2026